Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma by Galivo, F et al.
This is an author produced version of Single-cycle viral gene expression, rather than 
progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/87591/
Article:
Galivo, F, Diaz, RM, Wongthida, P et al. (5 more authors) (2010) Single-cycle viral gene 
expression, rather than progressive replication and oncolysis, is required for VSV therapy 
of B16 melanoma. Gene Therapy, 17 (2). pp. 158-170. ISSN 1476-5462 
https://doi.org/10.1038/gt.2009.161
© 2009, Nature Publishing Group. This is an author produced version of a paper accepted 
for publication Gene Therapy. Uploaded in accordance with the publisher's self-archiving 
policy.
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
Single-Cycle Viral Gene Expression, Rather Than Progressive
Replication and Oncolysis, Is Required for VSV Therapy of B16
Melanoma
Feorillo Galivo1, Rosa Maria Diaz1,2, Phonphimon Wongthida1, Jill Thompson1, Timothy
Kottke1, Glen Barber3, Alan Melcher4, and Richard Vile1,2,4,*
1Department of Molecular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905,
USA
2Department of Immunology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
3Department of Microbiology and Immunology and Sylvester Comprehensive Cancer Center,
University of Miami School of Medicine, Miami, FL 33136, USA
4Institute of Molecular Medicine, University of Leeds, Leeds, LS9 7TF, UK
Abstract
A fully intact immune system would be expected to hinder the efficacy of oncolytic virotherapy by
inhibiting viral replication. Simultaneously, however, it may also enhance antitumor therapy
through initiation of pro-inflammatory, antiviral cytokine responses at the tumor site. The aim of
the current study was to investigate the role of a fully intact immune system upon the antitumor
efficacy of an oncolytic virus. In this respect, injection of oncolytic Vesicular Stomatitis Virus
(VSV) into subcutaneous B16ova melanomas in C57Bl/6 mice leads to tumor regression, but it is
not associated with viral replicative burst in the tumor. In contrast, intratumoral delivery of VSV
induces an acute proinflammatory reaction, which quickly resolves concomitantly with virus
clearance. Consistent with the hypothesis that therapy may not be dependent upon the ability of
VSV to undergo progressive rounds of replication, a single-cycle VSV is equally effective as a
fully replication-competent VSV, whereas, inactivated viruses do not generate therapy. Even
though therapy is dependent upon host CD8+ and NK cells, these effects are not associated with
IFN-ś-dependent responses against either the virus or tumor. There is, however, a strong
correlation between viral gene expression, induction of proinflammatory reaction in the tumor and
in vivo therapy. Overall, our results suggest that acute innate antiviral immune response, which
rapidly clears VSV from B16ova tumors, is associated with the therapy observed in this model.
Therefore, the antiviral immune response to an oncolytic virus mediates an intricate balance
between safety, restriction of oncolysis and, potentially, significant immune-mediated antitumor
therapy.
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Introduction
Oncolytic Vesicular Stomatitis Virus (VSV) is a potent oncolytic agent against a variety of
both human and rodent tumors1-5 in both immunodeficient and immunocompetent
models.2,3,6-9 Infection of normal cells with VSV, a negative strand Rhabdovirus, induces
Type I IFN responses (IFN-ř/Ś), thereby blocking viral replication and extinguishing
infection. In contrast, many tumor cells have defects in their IFN response1,4,5 allowing
unhindered infection, and lysis of tumors.2,3,6 We have shown that delivery of oncolytic
VSV into B16ova melanomas growing in immune competent C57Bl/6 mice leads to tumor
regressions and cures of a proportion of animals.10-13 In the context of direct intratumoral
injection, VSV recruited multiple immune effectors into the tumors, of which both CD8+ T
cells and NK cells were critical for the antitumor therapy.10 These findings showed that
tumor destruction in this model may have at least two components. The first is presumably
contributed by the conventional effector mechanisms of oncolytic virotherapy, namely direct
tumor cell killing as a result of viral infection, replication and lysis.14,15 The second is
contributed by immune effectors, including, but probably not exclusively, CD8+ T cells and
NK cells. However, from our initial studies, it was unclear whether this immune–mediated
component of therapy is based upon innate or adaptive responses to either virus, tumor or
both, following the direct injection of VSV into the tumor.
The innate immune response against viral infection can be viewed simultaneously as both a
positive contributor to, as well as a negative detractor from, the overall potential of oncolytic
virotherapy.14-16 On one hand, a robust antiviral immune response to an oncolytic virus is an
important and necessary safety component. Correctly functioning innate and adaptive
responses ensure that the virus does not spread systemically and prevents widespread
toxicity. Indeed, one of the theoretical cornerstones for the development of many oncolytic
viruses has been that an intact antiviral innate immune response is fully operational in
normal cells but not in tumor cells.14-17 On the other hand, the antiviral immune response
has evolved specifically to sense, shut down, and clear viral infections as rapidly as possible
after they become evident in vivo. This activity acts to suppress ongoing viral replication,
limit viral-mediated oncolysis and inhibit therapeutic efficacy. As a result, strategies have
been devised specifically to suppress the innate response to virus infection at the tumor site
to enhance viral replication, spread and oncolysis.14,15,18,19
With respect to the adaptive response induced by oncolytic virotherapy, there is considerable
evidence that local tumor destruction can lead to the priming of antitumor T cell responses
and that these can enhance tumor clearance in vivo.20 In addition, viral replication within the
tumor inevitably leads to generation of antiviral T and B cell responses. However, exactly
how the balance between antiviral and antitumor immune priming is affected by different
viruses has not been extensively studied. In the case of VSV, we have reported that VSV-
associated proteins are immunologically dominant compared to much less immunogenic
tumor-associated antigens10. However, oncolytic VSV virotherapy was able to prime
specific T cell responses against tumor-associated antigens (TAA) expressed within the
B16ova tumors much more efficiently when either the virus itself was engineered to express
a TAA,10 or when the precursor frequency of TAA-specific T cells was artificially increased
prior to virotherapy by adoptive transfer of T lymphocytes.10 In addition, delivery of VSV to
B16ova tumor cells growing in the lymph nodes and spleen induced much more efficient
priming of antitumor T cell responses than if VSV-mediated tumor cell killing occurs in a
subcutaneous tumor.12,20 Therefore, VSV-mediated oncolysis is able to prime tumor-
specific T cell responses under the appropriate conditions. Tumor oncolysis with other
viruses, with different kinetics of infection and inherent immunogenicities, may significantly
alter the balance between antiviral and antitumor immune priming.20
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Therefore, at best, the immune system is currently viewed as a troublesome partner in an
uneasy truce with oncolytic virotherapy, contributing to its safety and, possibly, to its
efficacy at the level of adaptive T cell immunity to the tumor. At worst, antiviral immunity
is seen as an opponent to oncolytic virotherapy, restricting its scope and efficacy at the level
of viral clearance before tumor destruction can be achieved14,15,19. In the current report, we
describe a tumor model in which the ability of the oncolytic virus to undergo progressive
rounds of replication is irrelevant for antitumor therapy. In addition, the innate immune
response to intratumoral viral injection, which is itself responsible for very rapid viral
clearance, is also the major driver of antitumor therapy. Therefore, immunomodulatory
strategies aimed at enhancing the efficacy of oncolytic virotherapy should consider the
effects that such approaches may have on both the positive, as well as negative,
contributions that antiviral immune effectors (cells and cytokines) can have on antitumor
therapy.
Materials and Methods
Cell lines
Murine B16ova melanoma cells (H2-Kb) were derived from B16 cells by transduction with a
cDNA encoding for the chicken ovalbumin gene.21 Cell lines were grown in Dulbecco's
Modification of Eagle's Medium with 4.5 g/L glucose and L-glutamine without sodium
pyruvate (Mediatech, Herndon, VA, USA) supplemented with 10% (v/v) fetal bovine serum
(Life Technologies). All cell lines were monitored routinely and found to be free of
Mycoplasma infection.10
Viruses
VSV (Replication-competent)—VSV-XN2 is the parental VSV virus (Indiana Serotype)
(no transgene) from which all recombinant viruses were derived. This virus serves as the
control virus in experiments in which recombinant viruses expressing an additional
transgene (GFP or CD40L) are used. VSV-CD40L was constructed from VSV-XN2 as
described below, based upon the hypothesis that local expression of CD40L at the site of
tumor cell oncolysis would enhance activation of adaptive, tumor specific T cell responses
in treated mice. VSV-GFP (Indiana serotype) was a gift from Dr. Glen Barber and was
described previously.22 VSV-CD40L was constructed by PCR amplifying the mouse
CD40L gene from pCR2.1-CD40L, subsequently this PCR product was digested with the
restriction enzymes XhoI and NheI and ligated into the plasmid pVSV-XN2 (genomic
plasmid of VSV Indiana serotype and a kind gift from Dr. John Rose of Yale University) to
yield pVSV-CD40L. Recombinant VSV-CD40L and the parental VSV-XN2 were recovered
based on the method described previously.23,24 Bulk amplification of plaque-purified VSVs
were performed by infecting BHK-21 cells (MOI=0.01) for 24 hours. Filtered supernatants
were harvested and subjected to 2 rounds of 10% sucrose (10% w/v) in 1X PBS (Mediatech,
Inc., Herndon, VA, USA) cushion centrifugation at 27,000 rpm for 1 hour at 4°C. The
pelleted virus was resuspended in 1X PBS, aliquoted and kept at −80°C. VSVs were titrated
in BHK-21 using standard plaque assay.10
VSV (Single-cycle viruses)—Replication-defective VSV-XN2 and VSV-CD40L were
generated by deleting the glycoprotein gene based on a previously published method.25-28
Specifically, the same plasmids used above, i.e. pVSV-XN2 and pVSV-CD40L, were
digested with MluI and XhoI to remove the VSV G gene sequence, blunted with T4 DNA
polymerase, and ligated with T4 DNA ligase to yield the following plasmids: pVSVXN2ļG
and pVSV-CD40LļG, respectively. Viruses were recovered by co-transfecting 10 Ťg of
pVSV-XN2ļG or pVSV-CD40LļG with 3 Ťg pBS-N, 5 Ťg pBS-P, 4 Ťg pBS-G, and 1 Ťg
pBS-L (pBS plasmids were generously given by Dr. John Rose of Yale University) into
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BHK-21 cells previously transduced an hour before with a replication-defective vaccinia
virus encoding for T7 polymerase (MVA-T7), a kind gift from Dr. Roberto Cattaneo of
Mayo Clinic. The recovered viral supernatants were centrifuge-clarified (1200 rpm for 7
minutes), filtered through a 0.2- Ťm MILLEX® GP Syringe Filter Unit (Millipore,
Carrigtwohill, Co., Cork, Ireland), pelleted in 10% sucrose cushion as above, resuspended in
1X PBS, and stored at −80°C.
Titration of Single Cycle VSV—Single-cycle VSVs were titered in BHK cells
complemented with the VSV-G protein. 6-well plates (>90% confluent) of BHK cells were
transfected with pCMV-VSV-G plasmid for 8 hours, washed with PBS, and infected/
transduced with serial dilutions of single-cycle VSV for 2 hours, then overlaid with 2%
Noble agar. Plaques developed between 24-36 hours.
VSV (Physical and chemical inactivation)—Sucrose-purified VSVs were inactivated
using heat, ultraviolet (UV), and formalin. For heat inactivation, VSVs were diluted to a
concentration of 1×1010 pfu/mL in 1X PBS, aliquoted in 0.5 mL eppendorf tubes, and
heated to 99°C for 20 minutes. Inactivation by UV (ţ=254 nm) was performed by exposing
1×1010 pfu/mL (one mL per well in an uncovered 6-well plate) under 120,000 microjoules/
cm2 of UV light for 120 minutes using a CL-1000 Ultraviolet Crosslinker (UVP, LLC,
Upland, CA, USA). VSV was formalin-inactivated as described previously.29 Briefly, high-
titer, purified VSV was mixed with an equal volume of 0.1250% (v/v) formalin (Fisher
Scientific, Pittsburgh, PA, USA) in DMEM supplemented with 1% (v/v) FBS at 4°C for 18
hours. Prior to an in vivo experiment, formalin-fixed VSV was diluted in PBS to a final
concentration of 1×1010 pfu/mL.
Viral titer determination from in vitro studies—Cultures of either BHK-21 or
B16ova melanoma cells were grown overnight in 6 well plates (750,000 cells/well). Cells
were washed once with 1X PBS and infected with recombinant VSVs (MOI=1 unless
otherwise indicated) in plain DMEM for 1 hour at 37°C in a humidified 5% CO2 incubator.
Virus was siphoned out and replaced with regular culture media. Supernatants were
harvested at various time points, clarified, filtered, serially-diluted in plain DMEM, and
titrated in BHK-21 using a standard plaque assay.10
Viability assays—Overnight cultures of BHK-21 or B16ova melanoma cells (1×104 cells/
50ŤL medium/well) in 96-well plates (three replicate wells per sample) were infected with
50 ŤL of VSV (MOI=1.0) and incubated at 37°C in a humidified 5% CO2 incubator. At
indicated time points, cell viability was assessed using Cell Proliferation Kit I (MTT, Roche
Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's recommended
protocol.
Survival studies—All mouse in vivo protocols were approved by the Mayo Foundation
Institutional Animal Care and Use Committee. Female C57Bl/6 mice were purchased from
The Jackson Laboratories (Bar Harbor, ME, USA) at 6-8 weeks of age. To establish
subcutaneous tumors, 5×105 B16ova cells suspended in 100Ťl of 1X PBS were injected into
the right flanks of mice. Viral injections (5×108 pfu suspended in 50 Ťl 1X PBS) were
performed intratumorally at indicated time points after tumor seeding. In comparing VSV
and TLR-4 agonist, purified lipopolysaccharide or LPS (200 Ťg per dose) (Sigma-Aldrich,
St. Louis, MO, USA) was injected intratumorally three times on days 7, 9, and 11 after
subcutaneous implantation of B16ova cells.
Viral titer determination from in vivo studies—Established subcutaneous B16ova
melanoma tumors were intratumorally injected with a single dose of 5×108 pfu VSV. At
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indicated time points, mice were euthanized and tumors were harvested and placed in 2 mL
cryotubes and immediately snap-frozen in liquid nitrogen. To determine the viral titers,
tumors were homogenized in 1 mL 1X PBS and the supernatants were clarified, serially-
diluted in plain DMEM, and titrated in BHK-21 using a standard plaque assay.10
ELISPOT and ELISA analysis for IFN-Ȗ secretion—Spleens or tumor draining lymph
nodes were removed from mice at the indicated times. For ELISA, a million cells were
plated (unless otherwise indicated) in 24 well plates and incubated at 37°C with the
indicated peptides i.e., H-2Kb-restricted peptides TRP-2180-188 SVYDFFVWL, ova
SIINFEKL and VSV-N protein-derived RGYVYQGL were synthesized at the Mayo
Foundation Core facility. Cell-free supernatants were collected after 48 h and tested by
ELISA for IFN-ś (BD OptEIA™ Mouse IFN-ś ELISA Set; BD Biosciences Pharmingen,
San Diego, CA, USA). For ELISPOT assays (Mouse Interferon-ś ELISpotPlus, MABTECH
AB, Nacka Strand, Sweden) , 1 ×105 cells were plated into each well of a 96-well ELISPOT
plate in triplicates and were re-stimulated for 48 hours at 37°C under the different conditions
(all peptides were at 5 Ťg/ml). Peptide-specific IFN-ś positive spots were detected according
to the manufacturer's protocol and were quantified by computer assisted image analyzer.10
Flow cytometry—For analysis of phenotype, 1 × 106 cells were washed in 1X PBS
containing 0.1 % BSA and 0.01% sodium azide (FACS buffer), re-suspended in 50 Ťl of
FACS buffer, and exposed to fluorochrome-conjugated primary antibodies (anti-CD40LPE,
anti-I-Ab-PE, anti-CD45R/B220-PE, anti-CD4-FITC and anti-CD45-PerCP from BD
Pharmingen, CA, USA, and anti-VSV-G-FITC from Immunology Consultants Lab,
Newberg, OR, USA), for 30 min at 4°C. Cells were then washed and resuspended in 500 Ťl
of PBS containing 4% formaldehyde.10 Cells were subjected to flow cytometry and data
were analyzed using CellQuest software (BD Biosciences, San Jose, CA, USA) or FlowJo
(Tree Star, Inc., Ashland, OR, USA).
RT-PCR—Total RNA were extracted from either monolayer cultures or tumor samples
using RNeasy RNA purification kit (QIAGEN, Valencia, CA, USA) following the
manufacturer's suggested protocols. Reverse transcription was performed on 1 Ťg total
RNA/sample using First Strand cDNA synthesis kit (Roche Applied Science, Indianapolis,
IN, USA) according to the recommended procedure. The resulting cDNA was used as
template for PCR using the following mouse DNA primers: GAPDH-f: 5’-
aactttggcattgtggaagg-3’; GAPDH-r: 5’-tgtgagggagatgctcagtg-3’; RANTES-f: 5’-
gtgcccacgtcaaggagtat-3’, RANTES-r: 5’-atttcttgggtttgctgtgc-3’; PKR-f: 5’-
caaagcaggaggcaagaaac-3’; PKR-r: 5’-gctgactgggaaacaccatt-3’; IFN-Ś-r: 5’-
tcccacgtcaatctttcctc-3’; IFN-Ś-f: 5’-ataagcagctccagctccaa-3’; VSV-N-r: 5’-
agttccgtatctgaacgaggc-3’; VSV-N-f: 5’-acgaagacaaacaaaccattattatcattaa-3’; IRF3-f:5’-
caagcttgtgaaggagtacgtg-3’; IRF3-r: 5’-gtactggtcagaggtaagggagatag-3’; IRF7-f: 5’-
gtcacactatctgtggctacaacc-3’; IRF7-r: 5’-gtactgcagaacctgaagcaagag-3’; ISG56-f: 5’-
catcaccttcctctggctacttac-3’; and ISG56-r: 5’-gtgtgattctacagctcacaggag-3’. PCR products
were resolved in 1X TAE-1% agarose gel stained with ethidium bromide.
Statistics—Survival data from the animal studies were analyzed by Logrank test using
GraphPad Prism 4 (GraphPad Software, La Jolla, CA, USA). Immunological assays and
other in vitro experiments were analyzed using JMP® Software (SAS Institute, Inc., Cary,
NC, USA). Statistical significance was determined at the level of p<0.05.10
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Results
In vivo therapy is not associated with a replicative burst in B16ova tumors
In vitro, VSV replicates rapidly to high titers in B16ova cells (Fig. 1A, right) leading to
infection of between 90% to 100% of cells by 24 hours post infection, even at a low MOI
(Fig. 1A, left). Direct injection of VSV into established subcutaneous B16ova tumors is also
associated with significant therapy compared to either heat-inactivated virus (not shown) or
PBS (Fig. 1B). We also observed a partial dose-response of this therapy. Thus, therapy with
three intratumoral doses of 5×106, 5×107 or 5×108 pfu were all significantly more effective
than control treatment (p=0.0145; p=0.0001 or p<0.0001 respectively) (Fig. 1B) and
injections of 5×108 pfu were significantly better than 5×106 pfu (p=0.0244). Although we
observed a consistent trend to better outcome with tenfold stepwise increases in dose, these
did not reach significance (5×108 pfu vs. 5×107 pfu: p=0.1253; and 5×107pfu vs. 5×106pfu:
p=0.2569).
In contrast to the exponential increase of output virus seen in vitro (Fig. 1A, right), no such
replicative amplification was observed following intratumoral injection of established
subcutaneous B16ova tumors in vivo (Fig. 1C). In fact, viral titers consistently decreased
steadily and by the 10th day postinfection, no infectious VSV could be detected in the tumor.
Significantly, although increased doses of input virus improved therapy (Fig. 1B), they were
not associated with increased titers recovered from tumors. These data suggest that therapy
may not be exclusively associated with levels of viral replication within the tumors.
Intratumoral VSV induces rapid inflammation
Consistent with an immune-mediated shutdown of virus replication, intratumoral injection
of VSV into B16ova tumors was associated with an early-onset and very rapid induction of
proinflammatory cytokines at the tumor site and the draining lymph nodes (Fig. 1D, left
panels). The four cytokines induced include TNF-ř, IL-6, IFN-ś, and IFN-Ś, all of which
have reported antitumor activities.30-33 Importantly, this cytokine profile was almost
completely quenched within 3 days of the viral injection (Fig. 1D, middle panels) indicating
that the source of the inflammation (i.e. the virus) was probably fully cleared within a
relatively short time frame both at the tumor site and the draining lymph nodes. This potent,
local proinflammatory reaction was re-induced in tumors with similar kinetics following a
subsequent intratumoral VSV injection given 7 days following the first injection, but not in
the draining lymph nodes (Fig. 1D, right panels).
Consistent with the hypothesis that viral replication may not be the sole determinant of
VSV-mediated therapy in the B16ova model, we have also previously observed that therapy
absolutely requires both CD8+ and NK cells.10 For this reason, in separate studies, we
hypothesized that improving T cell priming by encoding the strong immune adjuvant
CD40L34 in VSV would further enhance antitumor efficacy. However, using either 2, 6 or 9
intratumoral injections, VSV-CD40L never generated significantly better therapy than VSV-
GFP (Galivo et al. Submitted). In addition to VSV therapy not being enhanced by co-
expression of a molecule which targets CD8+ T cell effector activity, VSV-mediated therapy
of B16ova tumors was not affected in host animals genetically deficient for the production
of IFN-ś (Fig. 1E).
Single-cycle VSV
Taken together, these data suggest that VSV-mediated therapy of B16ova tumors is
associated with neither a large replicative burst of intratumoral virus nor with the levels of
virus recovered from tumors. Although therapeutic efficacy is critically dependent upon host
immune cells, it is not dependent upon IFN-ś-mediated effector mechanisms. Moreover,
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intratumoral virus is associated with rapid induction of pro-inflammatory cytokines which
could potentially have significant antitumor activities. Therefore, we tested whether a virus
with no capacity to produce infectious progeny viruses would show similar therapeutic
efficacy in vivo as a fully replication competent VSV by generating single-replication cycle
VSV vectors (VSV-XN2-ļG and VSVCD40L-ļG) in which the gene encoding the VSV-G
glycoprotein was deleted (Fig. 2A). As expected, no infectious VSV particles were
recovered from culture supernatants of B16ova cells 24 hours following infection with
single-cycle VSVs (MOI=0.01) (Fig. 2B). Direct infection of B16ova cells with both VSV-
XN2-ļG and VSV-CD40L-ļG led to both significant cytotoxicity in vitro as a result of viral
gene expression (Fig. 2C), and to expression of the CD40L transgene, but no transfer of
expression of the VSV-G protein even at very high MOI of infection with the single cycle
viruses (Fig.2D/E). In contrast, direct infection with the replication competent counterparts
led to cytoxicity, transgene expression and transfer of VSV-G (Figs.2B-D). However, upon
exposure of fresh target cells to supernatants harvested from BHK cells infected with the
delta-G viruses, expression of neither the transgene, nor of VSV-G (Fig.2F), nor any
cytotoxicity, could be detected, although all three were readily transferred through multiple
passages from supernatants of cells initially infected with replication competent viruses(Fig.
2F). Taken together, the data in Figs.2B-F, confirm the replication defective, single cycle
nature of the delta-G viruses.
Single cycle VSV are effective antitumor agents
Levels of transduction of tumors with the CD40L transgene were indistinguishable
following a single intratumoral injection of VSV-CD40L-ļG or VSV-CD40L (Fig. 3A).
This confirmed both that these viruses express their genes in vivo and that there is very little
viral spread in B16ova tumors following the initial infection with a replication-competent
virus. Intratumoral injections of either replication competent VSV-CD40L or single-cycle
VSV-CD40L-ļG virus consistently resulted in a significant prolongation in survival relative
to PBS-treated control groups (p=0.0001 in Fig. 3B). However, there was never any
significant difference between the therapeutic efficacy of replication-competent VSV-
CD40L compared to single cycle VSV-CD40L-ļG (Fig. 3B, p=0.8910) or between VSV-
XN2 and VSV-XN2-ļG (Supplemental Figure). Similar to replication-competent VSVs,
VSV-CD40L-ļG did not augment the oncolytic efficacy of the empty VSV-XN2-ļG
(p=0.2745) (Fig. 3C), confirming that the therapy is probably not operating through priming
of adaptive T cell responses. These data show that direct viral oncolysis beyond at least a
single round of infection has only a very limited contribution to therapeutic efficacy.
Immune responses to single-cycle VSV
Similar to replication-competent viruses, single-cycle viruses induced generally elevated
levels of T cell activation 7 days following intratumoral VSV injection (Fig. 4A). Although
these T cell responses were associated with specificity against VSV-derived epitopes, they
were not specific for the tumor associated TRP-2 or OVA antigens (Fig. 4A). Likewise, both
replication-competent and single-cycle viruses increased the numbers of CD45+ cells in the
tumor-draining lymph nodes to similar extents, and were all significantly higher than the
PBS group (VSV-CD40L: p<0.0001; VSV-CD40L-ļG: p=0.0105; VSV-XN2: p<0.0001)
(Fig. 4B). Both types of virus induced comparable levels of serum antibody titer, although
replication-competent VSV-CD40L significantly augmented levels of antiviral antibody
compared to either VSV-XN2 (p<0.0001) or VSV-CD40L-ļG (p<0.0001) (Fig. 4C).
However, this enhanced antiviral antibody response was not associated with increased
therapy (Figs. 3B,C). Finally, both replication-competent and single-cycle VSVs rapidly
induced interferon regulated genes within the tumor microenvironment, although induction
of IFN-Ś, RANTES, and ISG56 genes were consistently somewhat lower by replication–
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defective viruses compared to the replication competent viruses (Fig. 4D). Expression of
CD40L did not quantitatively influence these effects (Fig. 4D).
The nearly identical immune signatures of both types of virus following intratumoral
injection support the hypothesis that the antiviral innate response is a major contributor to
the antitumor effects in the B16ova model.
Viral gene expression is required for therapy
Next, we investigated whether viral antigen load alone is sufficient to trigger the antiviral
innate response associated with antitumor therapy, or whether viral gene expression is
required. To this end, we generated inactivated viral preparations which would contain
similar antigen loads but are incapable of even a single cycle of infection and viral gene
expression. Viral inactivation by heat (HI), exposure to ultraviolet (UVI), or by formalin-
fixation (FF) was confirmed by the inability of B16ova cells exposed to different inactivated
viral preparations in vitro to express viral glycoprotein G (Fig. 5A, top panels), to exhibit
CPE (Fig. 5A, bottom panels) or to be killed in vitro (Fig. 5B). Intratumoral injection of any
of the three inactivated viral preparations was, however, ineffective in generating antitumor
therapy compared to the replication competent viruses VSV or VSV-CD40L (Fig. 5C).
These results indicate that live, viable virus which can express its genome is required for
antitumor effects of VSV.
Antitumor VSV virotherapy is associated with an acute inflammatory response
We investigated the key correlates between viral properties and in vivo antitumor efficacy.
Only mice treated with live replication-competent virus, single-cycle replication defective
virus or with formalin-fixed inactivated virus generated both specific antiviral T cell
responses and elevated levels of non-specific T cell activation compared to PBS treated mice
(splenocytes pulsed with medium alone: VSV-CD40L: **p=0.0025; VSVCD40L-ļG:
*p=0.0214; FF-VSV: *p=0.0268; HI-VSV: p=0.3303; UVI-VSV: p=0.6529) (Fig. 6A). FF-
VSV also induced an antiviral antibody response comparable to that induced by replication-
competent virus (Fig. 6B). A good correlation was observed between viral forms associated
with in vivo antitumor therapy (live replication-competent or live single-cycle viruses) and
their ability to direct viral gene expression (Fig. 6C) and to induce expression of IFN-Ś and
other interferon-responsive genes such as RANTES, ISG56 and IRF7 in vivo (Fig. 6C).
However, induction of other IRGs such as PKR and IRF3 were not correlated with the
ability of different viral types to induce therapy (Fig. 6C).
These data suggest that the ability to generate antitumor therapy is associated with viral gene
expression (but not progressive replication) and its subsequent activation of an acute
proinflammatory response within the tumor. A prediction from these results would be that
an acute inflammatory agent may, therefore, be just as efficacious as a fully replication-
competent oncolytic virus upon direct intratumoral injection. Consistent with this, treatment
of B16ova tumors with the TLR-4 agonist lipopolysaccharide (LPS) (at the maximum
tolerated dose of 200 Ťg) was consistently as effective, if not more so, than a similar
regimen of replication-competent VSV at its maximum tolerated dose (Fig. 6D).
Discussion
We show here that, at least in the VSV/B16ova/C57Bl/6 model, the therapeutic efficacy of a
fully replication competent oncolytic virus does not depend upon its ability to replicate in
and through the tumor. In contrast, antitumor therapy results not from viral replication, but
from the antiviral immune response, which leads to significant levels of tumor cell killing.
These data suggest that there may even be negative therapeutic outcomes in some models if
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immune suppressive interventions are used which are directed at enhancing viral replication,
but which simultaneously diminish immune mediated, anti-viral tumor clearance
mechanisms. As such, the results presented here have important implications for the design
of future strategies aimed at improving the efficacy of virotherapy in immune competent
patients. These data further highlight the inevitable and persistent friction that exists in
reconciling the role played by the immune system in mediating the efficacy, inhibition, and
safety of oncolytic virotherapy.
Unlike the case in vitro, no sustained replicative burst of virus was detected in B16ova
tumors injected with VSV in vivo (Fig. 1C). It may be that active replication does occur
within these tumors but is counterbalanced by even more rapid clearance of newly-
synthesized virus. However, we believe that it is more likely that replication of VSV within
B16ova tumors does not occur at significant levels because it is shut down rapidly by an
acute, potent innate immune response (Fig. 1C). This inflammatory response is activated by
viral gene expression (Fig. 6C) and disappears within days, presumably correlating with
clearance of the inflammatory stimulus (i.e. the virus) (Fig.1C). The dose-response of
therapy with increasing levels of input virus was not associated with corresponding
increases in viral titers recovered from injected tumors. Therefore, therapy may not be
exclusively associated with levels of viral replication within the tumors.
Consistent with this lack of dependence upon viral replication, VSV-mediated therapy of
B16ova tumors is critically dependent upon intact host immune cells, including, but
probably not exclusively, CD8+ and NK cell compartments.10 However, VSV therapy was
neither enhanced by co-expression of a molecule which targets CD8+T cell effector activity
(Galivo et al. Submitted) nor was it diminished in mice genetically deficient for the
production of IFN-ś (Fig. 1E). Overall, these data suggest that an adaptive T cell response is
not a major component of VSV virotherapy of B16ova melanoma in C57Bl/6.
Based on these findings, we hypothesized that the antitumor therapy observed in this model
is predominantly due to the host immune response against the invading virus, as opposed to
progressive viral replication and oncolysis of tumor cells. One prediction of such a
hypothesis is that a virus with diminished capacity to replicate would show similar
therapeutic efficacy in vivo as a fully replication-competent VSV. Consistent with this
hypothesis, there was no difference between the ability of fully replication-competent VSV,
or replication-incompetent, single-cycle VSV to generate antitumor therapy (Fig. 3B).
Therefore, ongoing production of infectious VSV progeny is not required in this model for
tumor therapy, suggesting that direct viral oncolysis beyond at least a single round of
infection has only a very limited contribution to efficacy. Interestingly, both single-cycle
and fully replication-competent VSV induced nearly identical immune signatures following
intratumoral injection as they relate to T cell, antibody and rapidly induced innate
inflammatory immune responses (Fig. 4A-D). This is consistent with their indistinguishable
therapeutic efficacy (Fig. 3B, Supplementary Figure) and supports the hypothesis that the
antiviral innate response, rather than progressive viral replication and oncolysis, is the major
contributor to the antitumor effects in the B16ova model.
We were initially surprised that we did not observe large differences between the ability of
replication-competent and single-cycle viruses to induce interferon-regulated genes within
the tumor microenvironment. However, in the light of our other data presented here, this is
consistent with the fact that the replication-competent viruses are severely restricted in their
ability to replicate in vivo in the tumor; hence, we believe that the similar levels of interferon
response generated by both type of vector simply reflects the fact that there is minimal
progressive replication due to its rapid immune-mediated shutdown in vivo. Our original
rationale for the inclusion of CD40L in VSV was to increase the generation of adaptive,
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tumor specific T cell responses following viral mediated oncolysis. The fact that the CD40L
encoding virus also generated very similar levels of interferon responsive gene expression in
tumors is, once again, consistent with the hypothesis that minimal viral replication occurs
because of immune-mediated shutdown.
Despite the ability of formalin-fixed VSV to elicit both a generalized T cell activation, an
antiviral T cell response, and neutralizing anti-VSV antibodies, at levels similar to those
generated by replication competent/incompetent viruses (Fig. 6A,B), FF-VSV could neither
generate antitumor therapy (Fig. 5C) nor the acute proinflammatory innate response (Fig.
6C). Our experiments with various forms of inactivated virus also indicated that live, viable
virus, which can express its genome (Fig. 5A and 6C), is required for antitumor effects of
VSV. In addition, only live viable VSV optimally induced expression of IFN-Ś and other
interferon-responsive genes such as RANTES, ISG56 and IRF7 in vivo (Fig. 6C). Finally,
injection of a potent inflammatory agent such as LPS induced almost identical antitumor
therapy as intratumoral injection of fully replication-competent oncolytic VSV (Fig. 6D).
Although the innate immune signaling pathways induced by VSV and LPS probably differ,
these data are consistent with the mechanism of action of VSV as being not different from
that of a non-specific immune adjuvant in this model.
An important future direction will be to identify the immune mediators of the antitumor
therapy. Significantly, many of the cytokines induced intratumorally by VSV injection (Fig.
1D) are themselves associated with antitumor activity31,35,36 either through direct cytotoxic
effects or through the activation of further immune effectors. Experiments are currently
underway to dissect the critical components of the innate response to VSV using mice
deficient in immune signaling pathways, as well as in expression of effector cytokines. It
may eventually be possible to selectively boost those cytokine components involved in
enhancing tumor cell killing while inhibiting those responses involved in suppressing viral
replication. If these components can be functionally separated, it would be possible to
manipulate the antiviral innate response to optimize both immune-mediated and oncolytic
therapy.
We do not believe that the predominance of the immune-mediated, versus oncolytic,
antitumor effector mechanisms that we have characterized in the C57Bl/6-B16ova model, is
necessarily applicable to all experimental models of either VSV or other oncolytic viruses.
For example, a notable difference between our model and others is the lack of the replicative
burst that is observed in vivo. In studies in which VSV serves as a potent oncolytic agent
against a rat model of hepatocellular carcinoma, amplification of the input viral dose is
clearly seen as a result of replication within the tumor37,38. We hypothesize that differences
between the innate response of different tumor cell lines to viral infection will heavily
influence the ability of the corresponding tumors to support viral replication, persistence and
amplification in vivo. In addition, several other factors may affect the outcome of
intratumoral VSV injection, including the genetic strain of the host, the anatomical location
of the tumor and the local immune context in which it is growing.
Overall, our results raise further tensions in the already highly-strained relationship between
oncolytic virotherapy and the immune system. A robust antiviral immune response to an
oncolytic virus in normal, but not tumor, cells is an important and necessary safety
component. In contrast, the antiviral immune response acts to suppress ongoing viral
replication, limit virus-mediated oncolysis and inhibit therapeutic efficacy. In reality, not all
tumor cells have completely defective responses to antiviral type I interferons and there is
likely to be a wide spectrum in the magnitude and extent of the responses of different tumor
cells to (oncolytic) viral infection. It may be, therefore, that a significant innate response to
the virus either by the tumor cells themselves, or by the infiltrating stromal cells, contributes
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to bystander killing of tumor cells through direct or indirect immune mediated mechanisms.
We believe that this is the case in the B16ova model described here. Therefore, the antiviral
immune response can, simultaneously, be a) a critical mediator of antitumor therapy, b) a
potent inhibitor of viral replication and spread in the tumor and c) an essential safety barrier
preventing systemic toxicity.
Perception of the immune response to viral infection purely as limiting viral replication and
efficacy has led to strategies aimed at local inhibition of the innate response to viral
infection in efforts to increase oncolysis.16,19,39 These approaches are rational and have
shown success. However, we suggest that consideration be given to the exact type of
suppressive mechanisms that are used and their likely impact on extinguishing the possible
positive impact on antitumor therapy that such immune re-activities may have.
In summary, we show here that the antitumor therapy associated with intratumoral VSV
injection in the B16ova model is not dependent upon the ability of the virus to undergo
progressive rounds of replication. In contrast, therapy is most closely correlated with viral
gene expression which induces a pro-inflammatory reaction, an effect which is similar to
that induced by a non-specific immune adjuvant injected directly into the tumor. These data
further suggest that the nature and extent of the antiviral immune response to oncolytic virus
infection mediates an intricate balance between safety against systemic virus toxicity,
restriction of viral replication/oncolysis, and potentially significant immune-mediated
antitumor therapy. Therefore, strategies aimed at improving the efficacy of oncolytic
virotherapy through modulation of antiviral immunity should consider all three of these
possible effects in order to maximize the overall therapeutic outcome.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Intratumoral VSV induced an acute proinflammatory reaction at the tumor site
A. (Left panel) B16ova cells were infected with VSV-GFP and the percentage of infected
cells (GFP+ cells) were counted using flow cytometry at various time points. (Right panel)
Overnight monolayer cultures of B16ova cells were infected with either VSV-XN2 or VSV-
GFP (MOI=1.0). The number of infectious progeny viruses were determined from the
culture supernatants harvested daily for 3 days using standard plaque assay in BHK cells.
Values are averages of triplicate wells (+ SEM) and representative of two independent
experiments. B. Effect of VSV dose-escalation on the survival of C57Bl/6 mice (n=8 per
group) bearing subcutaneous B16ova tumors treated with three intratumoral injections of
replication-competent VSV. *p<0.05, **p<0.01, ***p<0.001. C. Seven-day old
subcutaneous B16ova tumors in C57Bl/6 mice (n=3 mice per group per time point) were
infected with a single intratumoral dose of either VSV-GFP or HI-VSV (both using 5×108
pfu), harvested right after injection and on indicated days postinfection. The number of
infectious virus was assayed using standard plaque assay. HI-VSV consistently gave no
detectable titers (indicated by arrows). Values are averages of three tumors (+ SEM). D.
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Established B16ova tumors in immunocompetent mice (n=3 mice per group) were injected
intratumorally with one dose of VSV (5×108 pfu), the injected tumors and corresponding
draining lymph nodes were harvested at indicated times, the total RNA was extracted and
used in a ribonuclease protection assay (RPA). The symbol (ˢ) corresponds to upregulated
cytokine mRNA, while each lane corresponds to a sample from one mouse. E. Kaplan-
Meier survival graph comparing the therapeutic efficacy of six intratumoral VSV in tumor-
bearing C57Bl/6 mice (B6) or IFN-ś knockout mice (IFN-śko). Total of 8 mice per
treatment group. *p<0.05, **p<0.01, ***p<0.001.
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Figure 2. Characteristics of replication-defective recombinant VSV in B16ova melanoma cells in
vitro
A. cDNA representing the viral genomes of recombinant VSVs flanked by T7 RNA
polymerase leader, T7 terminator, and hepatitis virus delta ribozyme (RBZ). VSV-XN2-ļG
and VSV-CD40L-ļG were generated by removal of the G segment from VSV-XN2 and
VSV-CD40L, respectively. B. 2×106 B16ova cells were infected with VSVs (MOI=0.01) for
24 hours and viral titers were measured in the supernatants. Values are averages of duplicate
samples ± SEM. C. Using 96-well plates, 5×103 B16ova melanoma cells were infected with
VSVs at an MOI of 1.0. The number of viable cells was measured using MTT assay at the
indicated time points postinfection (hpi). Values are averages of triplicate samples (+ SEM)
and representative of 2 independent experiments. D/E. B16ova cells were infected with
replication competent (VSV-XN2 or VSV-CD40L) or single cycle (VSV-XN2-ļG or
VSVCD40L-ļG) viruses in vitro at either low (replication-competent, MOI=0.001) or high
(single-cycle, MOI>100) viral concentrations. 12 hours postinfection, cells were analyzed
for expression of either viral VSV-G protein (D) or the CD40L transgene (E). F. Fresh BHK
cells were exposed to undiluted supernatants harvested 48 hours postinfection from BHK
cells infected with either replication competent VSV-XN2 (MOI=0.01), or single-cycle
VSV-XN2-ļG (MOI>100). Virus was allowed to expand in these cultures for 48hrs.
Supernatants were harvested again and used to infect fresh cultures of BHK cells. 24hrs
later, cells were analyzed for expression of the VSV-G protein by flow cytometry.
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Figure 3. Live replication-defective recombinant VSVs delayed the growth of established
subcutaneous B16ova tumors in immunocompetent mice
A. VSV-injected B16ova tumors (n=3 per treatment group) were harvested four days after
injection, dissociated to obtain single cell suspensions, and assayed for CD40L expression
using flow cytometry. B. Seven-day old subcutaneous B16ova tumors were injected
intratumorally six times with 5×107 pfu of either VSV-CD40L or VSV-CD40L-ļG. Tumor
growth and overall survival were monitored (n=8 per treatment group). C. Kaplan-Meier
survival plot of subcutaneous B16ova tumor-bearing C57Bl/6 mice treated with six
intratumoral injections (5×107 pfu/dose) of VSV-XN2-ļG or VSV-CD40L-ļG. *p<0.05,
**p<0.01, ***p<0.001.
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Figure 4. Effects of infecting B16ova with single-cycle recombinant VSVs on the adaptive and
innate immune responses
A. IFN-ś ELISPOT assay of splenocytes harvested seven days after the third intratumoral
virus injection. Two replicates of 1×105 splenocytes were plated in 96-well ELISPOT plates
and cultured for 48 hours in the presence of the indicated peptides. B. Inguinal draining
lymph nodes from mice treated with a single injection of intratumoral VSVs were harvested
4 days postinfection and assessed the frequency of CD45+ populations via flow cytometry.
Three inguinal lymph nodes were pooled into a single sample per treatment group. Flow
cytometric analysis of CD45+ populations were done in quadruplicates. C. From the same
groups of mice in (a), blood was collected and the average serum antibody titer against VSV
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was determined (n=3 per group). *p<0.05, **p<0.01, ***p<0.001. D. RT-PCR was
performed on total RNA from B16ova cells in vitro following 8 hours of infection with the
following viruses using an MOI=1.0.
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Figure 5. The effects of physical and chemical inactivation of replication-competent VSV on the
efficacy of VSV virotherapy
A. Overnight cultures of 2×106 B16ova cells were infected with VSVs (MOI=0.01) for 24
hours. Top panels show dot plots of B16ova cells depicting surface expression of VSV-G.
Representative photographs showing cytopathic effects (CPE) (bottom panels) after 24
hours. HI: Heat-inactivated VSV; UVI: ultraviolet-inactivated VSV; FF: Formalin-fixed
VSV. B. Using 96-well plates, 5×103 B16ova melanoma cells were infected with either live
or inactivated VSVs at an MOI of 1.0. The number of viable cells was measured using MTT
assay at the indicated time points postinfection. Values are averages of triplicate samples (±
SEM) and representative of 2 independent experiments. C. Kaplan-Meier survival plot of
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subcutaneous B16ova tumor-bearing C57Bl/6 mice treated with six intratumoral injections
of either live VSV or inactivated forms of VSV (5×108 pfu/injection). *p<0.05, **p<0.01,
***p<0.001.
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Figure 6. Immune responses after intratumoral injection of live and inactivated forms of VSV
and therapeutic efficacy of intratumoral TLR agonist in B16ova tumors
A. Subcutaneous B16ova tumors were infected with 3 daily injections of either live or
inactivated VSV (5×107 pfu/injection). Eight days after the last virus, spleens were
harvested, dissociated and incubated with one of the four antigens indicated. Total IFN-ś
spots (1×105 splenocytes/48h) were measured using ELISPOT (n=3 mice/group). B. At the
time of sacrifice (day 17 after tumor challenge), blood was also extracted and serum
neutralizing antibody titer was determined. *p<0.05, **p<0.01, ***p<0.001. C. RT-PCR for
type I interferon-responsive genes was performed on total RNA from subcutaneous B16ova
tumors—harvested 8 hours postinfection—given a single injection of 5×108 pfu either live
or inactivated VSV. D. Kaplan-Meier survival plot of B16ova tumor-bearing C57Bl/6 mice
(n=8 per group) treated with three (3) intratumoral injections of either VSV-GFP (5×108
pfu/dose) or 200 Ťg of lipopolysaccharide (LPS). *p<0.05, **p<0.01, ***p<0.001.
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